Congenital microtia patients: the genetically engineered exosomes released from porous gelatin methacryloyl hydrogel for downstream small RNA profiling, functional modulation of microtia chondrocytes and tissue-engineered ear cartilage regeneration.


Journal

Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208

Informations de publication

Date de publication:
28 Mar 2022
Historique:
received: 15 01 2022
accepted: 04 03 2022
entrez: 29 3 2022
pubmed: 30 3 2022
medline: 31 3 2022
Statut: epublish

Résumé

Mesenchymal stem cells (MSCs) exosomes were previously shown to be effective in articular cartilage repairing. However, whether MSCs exosomes promote mature cartilage formation of microtia chondrocytes and the underlying mechanism of action remains unknown. Additionally, some hurdles, such as the low yield and unsatisfactory therapeutic effects of natural exosomes have emerged when considering the translation of exosomes-therapeutics to clinical practices or industrial production. Herein, we investigated the roles of human adipose-derived stem cells (ADSCs) exosomes in modulating microtia chondrocytes and the underlying mechanism of action. Special attention was also paid to the mass production and functional modification of ADSCs exosomes. We firstly used porous gelatin methacryloyl (Porous Gelma) hydrogel with pores size of 100 to 200 μm for 3D culture of passage 2, 4 and 6 ADSCs (P2, P4 and P6 ADSCs, respectively), and obtained their corresponding exosomes (Exo 2, Exo 4 and Exo 6, respectively). In vitro results showed Exo 2 outperformed both Exo 4 and Exo 6 in enhancing cell proliferation and attenuating apoptosis. However, both Exo 4 and Exo 6 promoted chondrogenesis more than Exo 2 did. Small RNA sequencing results indicated Exo 4 was similar to Exo 6 in small RNA profiles and consistently upregulated PI3K/AKT/mTOR signaling pathway. Notably, we found hsa-miR-23a-3p was highly expressed in Exo 4 and Exo 6 compared to Exo 2, and they modulated microtia chondrocytes by transferring hsa-miR-23a-3p to suppress PTEN expression, and consequently to activate PI3K/AKT/mTOR signaling pathway. Then, we designed genetically engineered exosomes by directly transfecting agomir-23a-3p into parent P4 ADSCs and isolated hsa-miR-23a-3p-rich exosomes for optimizing favorable effects on cell viability and new cartilage formation. Subsequently, we applied the engineered exosomes to in vitro and in vivo tissue-engineered cartilage culture and consistently found that the engineered exosomes could enhance cell proliferation, attenuate apoptosis and promote cartilage regeneration. Taken together, the porous Gelma hydrogel could be applied to exosomes mass production, and functional modification could be achieved by selecting P4 ADSCs as parent cells and genetically modifying ADSCs. Our engineered exosomes are a promising candidate for tissue-engineered ear cartilage regeneration.

Sections du résumé

BACKGROUND BACKGROUND
Mesenchymal stem cells (MSCs) exosomes were previously shown to be effective in articular cartilage repairing. However, whether MSCs exosomes promote mature cartilage formation of microtia chondrocytes and the underlying mechanism of action remains unknown. Additionally, some hurdles, such as the low yield and unsatisfactory therapeutic effects of natural exosomes have emerged when considering the translation of exosomes-therapeutics to clinical practices or industrial production. Herein, we investigated the roles of human adipose-derived stem cells (ADSCs) exosomes in modulating microtia chondrocytes and the underlying mechanism of action. Special attention was also paid to the mass production and functional modification of ADSCs exosomes.
RESULTS RESULTS
We firstly used porous gelatin methacryloyl (Porous Gelma) hydrogel with pores size of 100 to 200 μm for 3D culture of passage 2, 4 and 6 ADSCs (P2, P4 and P6 ADSCs, respectively), and obtained their corresponding exosomes (Exo 2, Exo 4 and Exo 6, respectively). In vitro results showed Exo 2 outperformed both Exo 4 and Exo 6 in enhancing cell proliferation and attenuating apoptosis. However, both Exo 4 and Exo 6 promoted chondrogenesis more than Exo 2 did. Small RNA sequencing results indicated Exo 4 was similar to Exo 6 in small RNA profiles and consistently upregulated PI3K/AKT/mTOR signaling pathway. Notably, we found hsa-miR-23a-3p was highly expressed in Exo 4 and Exo 6 compared to Exo 2, and they modulated microtia chondrocytes by transferring hsa-miR-23a-3p to suppress PTEN expression, and consequently to activate PI3K/AKT/mTOR signaling pathway. Then, we designed genetically engineered exosomes by directly transfecting agomir-23a-3p into parent P4 ADSCs and isolated hsa-miR-23a-3p-rich exosomes for optimizing favorable effects on cell viability and new cartilage formation. Subsequently, we applied the engineered exosomes to in vitro and in vivo tissue-engineered cartilage culture and consistently found that the engineered exosomes could enhance cell proliferation, attenuate apoptosis and promote cartilage regeneration.
CONCLUSIONS CONCLUSIONS
Taken together, the porous Gelma hydrogel could be applied to exosomes mass production, and functional modification could be achieved by selecting P4 ADSCs as parent cells and genetically modifying ADSCs. Our engineered exosomes are a promising candidate for tissue-engineered ear cartilage regeneration.

Identifiants

pubmed: 35346221
doi: 10.1186/s12951-022-01352-6
pii: 10.1186/s12951-022-01352-6
pmc: PMC8962601
doi:

Substances chimiques

Hydrogels 0
Methacrylates 0
MicroRNAs 0
gelatin methacryloyl 0
Gelatin 9000-70-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

164

Subventions

Organisme : CAMS Innovation Fund for Medical Sciences
ID : 2017-I2M-1-007

Informations de copyright

© 2022. The Author(s).

Références

Cell Biol Toxicol. 2021 Feb;37(1):85-96
pubmed: 33099657
Plast Reconstr Surg. 2019 Nov;144(5):816e-827e
pubmed: 31385891
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Front Bioeng Biotechnol. 2021 Dec 02;9:770049
pubmed: 34926420
Tissue Eng Regen Med. 2021 Aug;18(4):685-691
pubmed: 34173219
Clin Cosmet Investig Dermatol. 2020 Dec 15;13:957-971
pubmed: 33364805
Int J Mol Sci. 2021 Apr 14;22(8):
pubmed: 33920046
Mol Pharm. 2020 May 4;17(5):1723-1733
pubmed: 32233440
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669940
Cancer Res. 2008 Jun 1;68(11):4229-38
pubmed: 18519682
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2016 Oct;33(5):916-22
pubmed: 29714945
J Extracell Vesicles. 2020 Jun 16;9(1):1778883
pubmed: 32939233
Cell Commun Signal. 2014 Apr 11;12:26
pubmed: 24725987
Mater Sci Eng C Mater Biol Appl. 2017 Jan 1;70(Pt 2):983-991
pubmed: 27772730
Am J Sports Med. 2010 Jun;38(6):1110-6
pubmed: 20392971
Osteoarthritis Cartilage. 2015 Feb;23(2):319-27
pubmed: 25452155
Front Cell Dev Biol. 2020 Nov 03;8:553444
pubmed: 33224943
J Orthop Res. 2013 Dec;31(12):1936-42
pubmed: 24038580
Biomaterials. 2019 Jun;206:87-100
pubmed: 30927715
Stem Cell Res Ther. 2020 May 27;11(1):206
pubmed: 32460853
Nanomaterials (Basel). 2020 Feb 29;10(3):
pubmed: 32121340
Am J Sports Med. 2015 Sep;43(9):2293-301
pubmed: 26113522
ACS Appl Mater Interfaces. 2020 Jun 17;12(24):26955-26965
pubmed: 32441910
Biomaterials. 2016 Oct;105:195-205
pubmed: 27522254
Cell Physiol Biochem. 2018;47(1):11-25
pubmed: 29763932
Biomaterials. 2020 Aug;249:120020
pubmed: 32305816
Biomacromolecules. 2009 Mar 9;10(3):541-6
pubmed: 19173557
Nature. 2022 Jan;601(7893):446-451
pubmed: 34937935
EBioMedicine. 2018 Feb;28:287-302
pubmed: 29396297
Nanoscale. 2022 Jan 20;14(3):797-814
pubmed: 34951427
Bioeng Transl Med. 2017 Jun 26;2(2):170-179
pubmed: 28932818
Adv Mater. 2020 Dec;32(51):e2002440
pubmed: 33015883
Front Physiol. 2018 Aug 24;9:1169
pubmed: 30197601
ACS Nano. 2021 Feb 23;15(2):3251-3263
pubmed: 33481565
Mol Ther. 2018 Dec 5;26(12):2838-2847
pubmed: 30341012
Biomater Sci. 2019 Sep 24;7(10):4248-4259
pubmed: 31393466
Adv Drug Deliv Rev. 2021 Sep;176:113843
pubmed: 34147532
J Transl Med. 2015 Jun 24;13:200
pubmed: 26104414
J Cell Physiol. 2019 Dec;234(12):21817-21824
pubmed: 30471105
Mol Cell Biochem. 2021 Mar;476(3):1411-1420
pubmed: 33389494
Biomaterials. 2017 Oct;141:74-85
pubmed: 28667901
Tissue Eng Part A. 2013 Aug;19(15-16):1852-61
pubmed: 23517496
Nan Fang Yi Ke Da Xue Xue Bao. 2021 Apr 20;41(4):483-494
pubmed: 33963706
Biomaterials. 2020 Feb;230:119571
pubmed: 31753474
Nat Nanotechnol. 2021 Jul;16(7):748-759
pubmed: 34211166
Biofabrication. 2021 Dec 03;14(1):
pubmed: 34798628
J Nanobiotechnology. 2022 Jan 6;20(1):25
pubmed: 34991615
Front Mol Biosci. 2020 Jun 24;7:119
pubmed: 32671095
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Osteoarthritis Cartilage. 2016 Dec;24(12):2135-2140
pubmed: 27390028
Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4
pubmed: 18077471
Cell Biol Toxicol. 2020 Apr;36(2):165-178
pubmed: 31820164
Nanomedicine (Lond). 2011 Aug;6(6):961-74
pubmed: 21707296
Small. 2021 Dec;17(50):e2101741
pubmed: 34288410
Biochem Biophys Res Commun. 2016 Sep 9;478(1):467-473
pubmed: 27318087
Cartilage. 2019 Apr;10(2):148-156
pubmed: 28805067
Biomaterials. 2014 Jun;35(18):4878-87
pubmed: 24656731
Nat Commun. 2019 Apr 9;10(1):1639
pubmed: 30967557
Cell Prolif. 2019 Sep;52(5):e12669
pubmed: 31380594
Biomaterials. 2018 Feb;156:16-27
pubmed: 29182933
J Extracell Vesicles. 2014 Sep 18;3:
pubmed: 25317274
Lab Invest. 2021 Sep;101(9):1254-1266
pubmed: 34045678
Acta Biomater. 2021 Apr 15;125:253-266
pubmed: 33657452
Stem Cell Res. 2020 Dec 10;50:102122
pubmed: 33316600
Plast Reconstr Surg. 2017 Apr;139(4):911e-921e
pubmed: 28350666

Auteurs

Jianguo Chen (J)

Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 33 Badachu Road, Shijingshan District, Beijing, 100144, People's Republic of China.

Tianyu Huang (T)

Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 33 Badachu Road, Shijingshan District, Beijing, 100144, People's Republic of China.

Ruiquan Liu (R)

Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 33 Badachu Road, Shijingshan District, Beijing, 100144, People's Republic of China.

Chenyu Wang (C)

Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 33 Badachu Road, Shijingshan District, Beijing, 100144, People's Republic of China.

Haiyue Jiang (H)

Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 33 Badachu Road, Shijingshan District, Beijing, 100144, People's Republic of China. jianghypsh@163.com.

Hengyun Sun (H)

Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 33 Badachu Road, Shijingshan District, Beijing, 100144, People's Republic of China. sunhengyun@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH